The detection of Alzheimer’s disease through a simple blood test is now a scientific reality. A recent study led by researchers from the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Center (BBRC), part of the Pasqual Maragall Foundation, has confirmed that a blood-based biomarker, phospho-tau217, can accurately indicate the risk of Alzheimer’s in individuals showing symptoms of cognitive impairment.
The study, published in Nature Medicine, was conducted in collaboration with the University of Gothenburg and Lund University in Sweden, as well as the University and Hospital of Brescia in Italy.
Researchers analyzed data from 1,767 individuals across five cohorts: four hospital-based groups from Hospital del Mar, Gothenburg Hospital, Malmö Hospital, and Brescia Hospital, and one primary care group in Sweden. Building on earlier research, the team validated the effectiveness of phospho-tau217 as a blood biomarker for identifying Alzheimer’s risk, even in the early, preclinical stages of the disease.
Now, they have validated an automated and scalable blood test system, Lumipulse p-tau217, developed by the Japanese company Fujirebio, to determine the threshold levels above or below which it can be confirmed whether a person will develop the disease or is free of risk.
…
